These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://janicedysb420565.blogadvize.com/47320786/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide